Defective complement activity in chronic lymphocytic leukemia

Heath, Margo E.; Cheson, Bruce D.

doi:10.1002/ajh.2830190109

Cited by 43 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a prospective study we addressed the possible association between depressed classical complement pathway activities frequently associated with CLL [1][2][3] and the clinical course of the disease. In these patients, low complement values are most probably the consequence of constantly ongoing complement activation [13] due to interaction of the CLL cells, immune complexes, anti-idiotype antibodies or other factors with the complement system.…”

Section: Discussionmentioning

confidence: 99%

Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia

Varga

Czink

Miszlai

et al. 1995

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYThe activities of the classical (CP) and alternative (AP) complement pathways as well as the levels of some complement components and circulating immune complexes were measured in 43 patients with chronic Iymphocytic leukaemia (CLL) between 1980 and 1984. Depressed CP activities were frequently found in these patients. Clinical course ofthe disease in the patients was followed until 1992, and compared with the initial complement values. During the follow-up period 36 patients died, death of 33 patients being related to the underlying disease. A strong positive correlation (P < OOI) was found between the length of survival of the patients and the initial CP values. Patients were divided into two groups: group A, short-term survivors, i.e patients who died in CLL-related complications within 3 years after the complement measurements; and group B. longterm survivors who died ^ 4 years after the complement measurements due to any cause, or were alive at the end of the follow-up period. Average CP values in Group B were almost twice those in group \ {P = 0-002), and a similar but less pronounced difference was found in C3 levels {/* = 0-055). These differences were even more marked (/* = 0 0006 and /* = 0 0015, respectively) when only patients in Rai stage 2 and 3 were considered. Low classical pathway activities predicted short survival time: according to the logrank test, patients in Rai stage 2 3 with low (

show abstract

Section: Discussionmentioning

confidence: 99%

Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia

Varga

Czink

Miszlai

et al. 1995

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Heath et al23 showed reduced serum complement levels in CLL patients. Complement plays a crucial role in the control of some bacterial infections; opsonization with complement is necessary for subsequent interactions with neutrophils.…”

Section: Pathogenesis Of Infectionmentioning

confidence: 98%

Infectious Complications in Chronic Lymphocytic Leukemia

Nosari¹

2012

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Infectious complications have been known to be a major cause of morbidity and mortality in Chronic Lymphocytic Leukemia (CLL) patients who are prone to infections because of both the humoral immunodepression inherent to the hematologic disease and to the immunosuppression related to the therapy. The majority of infections in CLL patients treated with alkilating agents is of bacterial origin. The immunodeficiency and natural infectious history of alkylator-resistant, corticosteroid-treated patients appears to have changed with the administration of purine analogs, which has been complicated by very severe and unusual infections and also more viral infections due to sustained reduction of CD4-positive T lymphocytes. The subsequent introduction of monoclonal antibodies in therapies, in particular alemtuzumab, further increased the immunodepression, increasing also infections which appeared more often in patients with recurrent neutropenia due to chemotherapy cycles.Epidemiological data regarding fungal infections in lymphoproliferative disorders are scarce. Italian SEIFEM group in a retrospective multicentre study regarding CLL patients reported an incidence of mycoses 0.5%; however, chronic lymphoproliferative disorders emerged as second haematological underlying disease after acute leukemia in a French study on aspergillosis; in particular CLL with aspergillosis accounted for a third of these chronic lymphoproliferative diseases presenting mould infection.

show abstract

“…Patients with chronic lymphocytic leukemia are at an increased risk for infections with bacteria which require complement for osponization (Heath & Cheson, 1985). Patients with chronic leukemias typically are affected by infections due to the underlying hematologic condition, particularly hypogammaglobulinemia in CLL patients.…”

Section: Bacterial Infectionmentioning

confidence: 99%

Infectious Diseases and Clinical Complications During Treatment in CLL

Abbasi¹

2012

Chronic Lymphocytic Leukemia

View full text Add to dashboard Cite

Defective complement activity in chronic lymphocytic leukemia

Cited by 43 publications

References 39 publications

Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia

Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia

Infectious Complications in Chronic Lymphocytic Leukemia

Infectious Diseases and Clinical Complications During Treatment in CLL

Contact Info

Product

Resources

About